MR/Ultrasound Fusion Biopsy for a Targeted Diagnosis

Loading the player ...

Dr. Alexander Kutikov describes the fusion biopsy system Fox Chase Cancer Center uses to better assure that tumors are located precisely in a prostate biopsy. (2:46)


Who Is a Candidate for an
MR/Ultrasound Fusion Biopsy?

 

Candidates include:

  • Patients with an elevated prostate-specific antigen (PSA) level

  • Patients with a negative prior prostate biopsy with continued elevation or rising PSA

  • Patients on Active Surveillance for prostate cancer who require rebiopsy

What a Fusion Biopsy Provides

MR/ultrasound fusion biopsy is a powerful diagnostic tool for the analysis, planning, and targeted biopsy of the prostate.

It is a complete clinical MR (magnetic resonance) solution that offers a truly new biopsy option for many patients with elevated and/or rising PSA (prostate-specific antigen) levels. It may effectively detect tumors in men with prior negative biopsies but persistently elevated PSA levels.

The technology fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time to create a detailed, three-dimensional view of the prostate, reducing chances that an aggressive form of prostate cancer is missed.

Biopsies are mapped, targeted, and tracked. The process typically involves a 20-minute procedure done in an outpatient setting under local anesthesia. The result is excellent delineation of the prostate as well as suspicious lesions.

Fusion Biopsy compared to a Traditional Biopsy

Fox Chase Cancer Center and Temple University Hospital were the first sites in the area to offer targeted MR/ultrasound fusion biopsy.

This innovative technology may result in fewer needle biopsies and better treatment decisions for patients with prostate cancer.

In a traditional core needle biopsy, urologists use a fine needle to collect a number of tissue samples from the prostate gland, which are then examined for cell abnormalities that are a sign of prostate cancer. Whereas the traditional method lacks precision and uses random prostate sampling, MR/ultrasound fusion biopsy helps urologists to avoid missing hard-to-find, yet often aggressive prostate cancer. the technology offers the potential to minimize the overdiagnosis of non-aggressive cancers, while maximizing the likelihood of detecting aggressive tumors.

Biopsies guided by MR/ultrasound fusion enable both physicians and patients to make more informed decisions ranging from prostate cancer diagnosis to treatment options—such as active surveillance or more radical interventions.

Uronav Fusion Biopsy System by Invivo

The Philips Invivo/UroNav system was developed in collaboration with the National Cancer Institute/National Institutes of Health (NIH) of the United States. It uses an electromagnetic field generator for co-registration of imaging and allows for prospective targeting and freehand manipulation using a standard TRUS probe.

[10/20/2014]

Request an Appointment

UroNav is an integrated, image-guided stereotactic system that uses magnetic resonance (MR) and ultrasound (US) images in conjunction with electromagnetic (EM) tracking devices to plan, guide and document clinical interventions.
[Images courtesy Invivo]

See National Cancer Institute information on Prostate Cancer
Prostate Cancer Risk Assessment Program

For men who have a family history or other risk factors for prostate cancer. Learn more »